Berna, Ronald http://orcid.org/0000-0003-0520-1218
Mitra, Nandita http://orcid.org/0000-0002-7714-3910
Hoffstad, Ole http://orcid.org/0000-0002-0261-903X
Wubbenhorst, Bradley http://orcid.org/0000-0001-8489-3659
Nathanson, Katherine L. http://orcid.org/0000-0002-6740-0901
Margolis, David J. http://orcid.org/0000-0002-0506-8085
Funding for this research was provided by:
national institute of arthritis and musculoskeletal and skin diseases (NIAMS R01-AR070873)
valeant pharmaceuticals international
Article History
Received: 28 July 2021
Revised: 8 December 2021
Accepted: 21 December 2021
First Online: 4 January 2022
Declarations
:
: David Margolis is a consultant for Pfizer with respect to studies of atopic dermatitis and serves on an advisory board for the National Eczema Association. No other authors state financial conflicts of interest with respect to this investigation.
: The PEER study was approved by the Institutional Review Board of the University of Pennsylvania, and written informed consent was obtained from all participants from the participant or his or her caregiver.